T. Rowe Price Associates’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

T. Rowe Price Associates’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-885,332	Closed	-$95M	–	2999
2023 Q1	$95M	Buy	885,332 +430,273	+95%	+$49.5M	0.01%	520
2022 Q4	$50.1M	Buy	455,059 +359,970	+379%	+$23.3M	0.01%	660
2022 Q3	$5.61M	Buy	+95,089	New	+$4.35M	﹤0.01%	1179
2021 Q2	–	Sell	-525,000	Closed	-$9.59M	–	2964
2021 Q1	$9.59M	Buy	+525,000	New	+$10.8M	﹤0.01%	1402

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

T. Rowe Price Associates's RXDX Position: Q2 2023 in Review

T. Rowe Price Associates sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 885,332 shares — an estimated $95M sold.

T. Rowe Price Associates first reported a position in RXDX in Q1 2021 and held it in 4 quarters. The position peaked at $95M in Q1 2023. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

T. Rowe Price Associates reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
T. Rowe Price Associates sold 885,332 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $95M.
T. Rowe Price Associates first reported a position in Prometheus Biosciences, Inc. Common Stock in Q1 2021 and held it in 4 quarters.
T. Rowe Price Associates's Prometheus Biosciences, Inc. Common Stock position peaked at $95M in Q1 2023.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on T. Rowe Price Associates's 13F filing for Q2 2023, filed 14 Aug 2023.